Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World study shows rybelsus lowers blood sugar in type 2 diabetes

NCT ID NCT05230615

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 35 times

Summary

This study looked at how well Rybelsus (oral semaglutide) works for adults with type 2 diabetes in Italy. Researchers tracked blood sugar levels and weight changes over 8-10 months in 458 people already prescribed the drug by their doctor. The goal was to see if the medicine helps control diabetes in real-world settings, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • IRCCS MultiMedica

    Sesto San Giovanni, Italy

  • Master Centre for Italy

    Rome, 00144, Italy

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.